Stock & Company Details
4D Molecular Therapeutics Inc $FDMT
Price:
46,691,331
52M
$695M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-9.07
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
FDMT technical indicators
Latest 4D Molecular Therapeutics Inc (FDMT) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
68.27 9.4%
MACD:
0.90 6.8%
SMA 50:
$9.75 0.5%
SMA 200:
$9.44 0.3%
EMA 20:
$10.80 1.9%
Bollinger Bands:
13.32 / 7.18
Stochastic:
85.08 3.1%
ADX 14:
29.40 6.5%
ATR 14:
0.93 0.2%
CCI 20:
134.98 26.7%
OBV:
29.31M 3.5%
ROC 12:
43.71% 13.4%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
Finance Bot
Ask your questions
Start by typing a question below.
